Patents by Inventor Yinjia GAO

Yinjia GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11786609
    Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: October 17, 2023
    Assignee: PURECODON (HONG KONG) BIOPHARMA LIMITED
    Inventors: Ke Huang, Chaoxuan Jing, Yingwen Li, Yinjia Gao, Yuping Liu, Zhenhua Sun
  • Patent number: 11690922
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: July 4, 2023
    Assignee: Purecodon (Hong Kong) Biopharma Ltd.
    Inventors: Ke Huang, Binxi Ge, Yingwen Li, Yuping Liu, Yinjia Gao, Zhenhua Sun
  • Publication number: 20230093138
    Abstract: The present invention belongs to the technical field of gene therapy, and particularly relates to a series of lipid compounds as well as a lipid carrier, nucleic acid lipid nanoparticle composition and pharmaceutical preparation containing the same. A compound having a structure of a formula (I) provided by the present invention can be used for preparing a lipid carrier together with other lipid compounds, and exhibits pH response, and the entrapment efficiency to a nucleic acid drug is high, which greatly improves in-vivo delivery efficiency of the nucleic acid drug; and furthermore, a lipid compound with a specific structure can be chosen as a lipid carrier based on an organ in which the nucleic acid drug needs to be enriched, having a good market application prospect.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 23, 2023
    Inventors: Ke HUANG, Binxi GE, Yingwen LI, Yuping LIU, Yinjia GAO, Zhenhua SUN
  • Publication number: 20220378938
    Abstract: The present disclosure belongs to the technical field of gene therapy, and specifically relates to a series of lipid compounds as well as lipid vectors, nucleic acid lipid nanoparticle compositions, and pharmaceutical preparations containing the same. The compound having the structure of formula (I) provided by the present disclosure may be used in combination with other lipid compounds to prepare a lipid vector, which exhibits pH responsiveness, has high encapsulation efficiency for nucleic acid drugs, and greatly enhances the in-vivo delivery efficiency of nucleic acid drugs. Moreover, it is possible to select lipid compounds with different structures as lipid vectors to adjust the enrichment of nucleic acid drugs in different organs, thereby having good market application prospect.
    Type: Application
    Filed: July 26, 2022
    Publication date: December 1, 2022
    Inventors: Ke HUANG, Chaoxuan JING, Yingwen LI, Yinjia GAO, Yuping LIU, Zhenhua SUN
  • Publication number: 20220257798
    Abstract: The present invention discloses H2O2 responsive crosslinking NIR molecular probe for tumor microenvironment and application therefor. The preparation method includes the following steps: the amide condensation of 2-propynylamine and Fmoc-Lys(Boc)-OH to obtain compound A01-01; removing protecting groups from compound A01-01, to obtain compound C1-2; reacting compound C1-2 and NHS-activated (3-carboxypropyl)triphenylphosphonium bromide, to obtain compound C1-3; removing protecting groups from compound C1-3, to obtain compound C1-4; reacting compound C1-4 with NHS-activated 3,5-dioxocyclohexane carboxylic acid, to obtain a compound C1-5; and reacting compound C1-5 with NIR dye, to obtain a H2O2 responsive crosslinking NIR molecular probe for tumor microenvironment.
    Type: Application
    Filed: July 27, 2020
    Publication date: August 18, 2022
    Inventors: Haibin SHI, Yinjia GAO